The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $5,725,286 in first-year total cost, median $1,837,542.
Most frequent study sections
- Special Emphasis Panel[ZDA1 SXC-M (O1)]3
Most frequent institutions
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE1
- UNIVERSITY OF UTAH1
- VIRGINIA COMMONWEALTH UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Psilocybin-Assisted Treatment of Cocaine Use Disorder1UG3DA062112-01 | ARIAS, ALBERT JOSEPH | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $643,019 | ZDA1 |
| 2024 | Evaluation of psilocybin as an adjunctive treatment for opioid use disorder in methadone-maintained patients who continue to use illicit opioids1UG3DA062088-01 | BOGENSCHUTZ, MICHAEL PARKS | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $3,244,725 | ZDA1 |
| 2024 | Targeting Treatment-Resistant OUD with Ketamine-Assisted Mindfulness-Oriented Recovery Enhancement1UG3DA062106-01 | GARLAND, ERIC LEENUNES, EDWARD V. | UNIVERSITY OF UTAH, UT | $1,837,542 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.